ASH 2023

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

10:00 PM

Duration 15mins Ballroom 20AB

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Jardin F, Raghavan V, Tracy S, Balasubramanian S, Sehn LH, Flowers CR, Morschhauser F, Herrera AF, Trněný M, Sharman JP, Salles G, Tilly H, Friedberg JW, Harris W, Hirata JH, Lee C, Jiang Y, Lenz G

Oncology | Diffuse large B cell lymphoma

01:30 AM

Duration 2hrs San Diego, USA

The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States

Bachiashvili K, Harada S, Ma E, Patel A, Wang R, Yellow-Duke A, Montez M, Chopra V, Bui CN, Vachhani P

Oncology | Acute Myeloid Leukemia

Duration 2hrs San Diego, USA

ASH 2023 Trials in progress: The randomized, double-blind, placebo-controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c trials – Crovalimab for vaso-occlusive episodes (VOEs) in sickle cell disease (SCD)

Araujo MA, Antmen B, Chite FA, Chonat S, de Franceschi L, Eleftheriou P, Inati A, Mahlangu J, Nur E, Payán Pernía S, Charania A, Gradinaru D, Hsia A, Luder Y, Perretti T, Sreckovic S, Bartolucci P

Hematology | Paroxysmal Nocturnal Hemoglobinuria

Duration 2hrs San Diego, USA

Co-expression of GPRC5D, FcRH5, and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma: Biomarker Results From the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

Dekhtiarenko I, Lelios I, Jacob W, Schneider M, Wiesser M, Carlo-Sella C, Manier S, Harrison SJ, Popat R, Hasselbalch Riley C, Bröske AME

Oncology | Multiple Myeloma

Duration 2hrs San Diego, USA

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Kiialainen A, Pipe SW, Fijnvandraat K, Kenet G, Schmitt C, Buri M, Jimenez-Yuste V, Oldenburg J, Mancuso ME, Dhalluin C, Lehle M, Collins P

Hematology | Hemophilia A

Duration 2hrs San Diego, USA

Experience with Emicizumab among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Poon MC, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Polito L, Moreno K, Santos M, Iserman E, Matino D, Iorio A

Hematology | Hemophilia A

Duration 2hrs San Diego, USA

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Harrup R, Kater AP, Eichhorst B, Owen C, Chyla B, Jin HY, Jiang Y, Chang YM, Millen R, Lefebure M, Thadani-Mulero M, Boyer M, Seymour JF

Oncology | Chronic Lymphocytic Leukemia

Duration 2hrs San Diego, USA

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Bottos A, Lutterbeck C, Bolen CR, Shin M, Bogard PE, Tabari E, Davies A, Knapp A, Nielsen T, Weigert O, Penuel E

Hematology | Follicular Lymphoma

05:30 PM

Duration 15mins Grand Hall D

Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Zelenetz A, Diefenbach C, Herbaux C, Tani M, Houot R, Bastos-Oreiro M, Tilly H, Gastinne T, Thieblemont C, Troy-Barnes E, Olivieri S, Kesavan M, Kanwar M, Barlera S, Hatzi K, Jiang Y, Boyer M, Morschhauser F

Oncology | Diffuse large B cell lymphoma

Duration 15mins Seaport Ballroom ABCD

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-cell Therapy and by Baseline Total Metabolic Tumor Volume

Hutchings M, Carlo-Stella C, Morschhauser F, Falchi L, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody J, Leppä S, Baumlin P, Mulvihill E, Relf J, Chohan S, Kaufman D, Lundberg L, Dickinson M

Oncology | B Cell Lymphoma

08:00 PM

Duration 15mins Room 29

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Pipe S, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Chang T, Lehle M, Niggli M, Fijnvandraat K

Hematology | Hemophilia A

12:30 AM

Duration 15mins Ballroom 20AB

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients with Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw L-Y, Wu H, To I, Wei MC, Chavez JC

Oncology | B Cell Lymphoma

Duration 15mins Room 7

Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies

Röth A, Fu R, He G, Alzahrani H, Chou S, Hicheri Y, Kazmierczak M, Lacorte Recova V, Uchiyama M, Vladareanu A, Beveridge L, Buatois S, Buri M, Shi D, Balachandron N, Srekovic S, Scheinberg P

Hematology | Paroxysmal Nocturnal Hemoglobinuria

12:45 AM

Duration 15mins Ballroom 20AB

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter’s Transformation

Cheah CY, Assouline S, Baker R, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Schuster SJ, Matasar M, Radford J, Wei MC, Yin S, To I, Tracy S, Kwan A, Budde LE

Oncology | Richters transformation

01:00 AM

Duration 15mins Grand Hall C

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-Up from a Pivotal Phase II Study

Schuster SJ, Sehn LH, Bartlett NL, Matasar M, Assouline S, Giri P, Kuruvilla J, Shadman M, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, To I, Tracy S, Kwan A, Penuel E, Budde LE

Oncology | Follicular Lymphoma

01:30 AM

Duration 15mins Grand Hall C

Preliminary findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide in Previously Untreated Follicular Lymphoma Requiring Therapy

Morschhauser F, Patel K, Cordoba R, Eyre TA, Bishton M, Houot R, Zhang H-L, Zou L, Osborne W, Galvez-Carvajal L, Thieblemont C, Yee DL, Knapp A, Purev E, Li H, Chen V, Banta KL, Sit J, Bachy E

Oncology | Follicular Lymphoma

02:00 AM

Duration 5mins San Diego, USA

Comparison of a Projected Hemophilia A Population Residing in Hospital Referral Regions With and Without Hemophilia Treatment Centers in the United States

Maria E. Santaella, Karina Raimundo, Robert Schuldt, Michael Recht

Hematology | Hemophilia A

Duration 5mins San Diego, USA

Cost-effectiveness of Emicizumab vs Efanesoctocog Alfa, Standard Half Life (SHL) and Other Extended Half Life (EHL) FVIII products for Prophylaxis in People with Severe Hemophilia A Without Inhibitors

Randall Curtis, Marquita Decker-Palmer, Michele R Wilson, Cheryl L McDade, Chia-Wei Lin, Chris Wallick, Richard H Ko

Hematology | Hemophilia A without Inhibitor

Duration 2hrs San Diego, USA

Dexamethasone is Associated With a Lower Incidence and Severity of Cytokine Release Syndrome Compared With Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Falchi L, Carlo-Stella C, Morschhauser F, Dickinson M, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody J, Leppä S, Berthier A, Kallemeijn M, Relf J, Chohan S, Lundberg L, Hutchings M

Oncology | B Cell Lymphoma

Duration 2hrs San Diego, USA

GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Phillips T, Matasar M, Eyre TA, Giné E, Filézac de L'Etang A, Byrne B, Lundberg L, Padovani A, Boetsch C, Bottos A, Qayum N

Oncology | Mantle Cell Lymphoma

Duration 2hrs San Diego, USA

Cytokine Release Syndrome: The Patient, Carer, and Healthcare Professional Experience

Soong J, De Carlo G, Lasi-Tejani N, Sethi SK, Bolaños N, Elias M, Biru Y, Clavreul S, Chandler GS, Finzler K, Nouet Y, Del Santo A

Oncology | Hematological Cancer

Duration 2hrs San Diego, USA

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Morschhauser F, Leung W, Raghavan V, Lenz G, Jardin F, Herrera AF, Sehn LH, Sharman JP, Flowers CR, Friedberg JW, Trněný M, Tilly H, Herbaux C, Tracy S, Bolen CR, Harris W, Hirata JH, Lee C, Jiang Y, Batlevi CL, Salles G

Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL)

Hamidi H, Kimes P, Schroeder AV, Uzunovic J, Olszewski AJ, Sit J, Purev E, Yee D, McCord R

Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

New Tocilizumab (TCZ) Dosing Guidance for T-cell Engaging Bispecific Antibody-Related Cytokine Release Syndrome (CRS) in Patients With Relapsed/Refractory (R/R) B-cell non-Hodgkin Lymphoma (B-NHL): Insights From Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qCP) Analyses

Jamois C, Turner DC, Gibiansky L, Li F, Frey N, Menuet J-F, Pereira LR, Lundberg L, Guerini E, Carlile D, Relf J, Wei MC, Kwan A, Grange S

Oncology | Non Hodgkin Lymphoma

Duration 2hrs San Diego, USA

Subcutaneous Mosunetuzumab is Active and has a Manageable Safety Profile in Patients With Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results From the Phase II MorningSun Study

Flinn IW, Budde LE, Tun AM, Burke JM, Anz B, Peles S, Sharman JP, Tumula PK, Biondo JML, Jani P, Wu M, Lin T, Parmar N, Mun Y, Yao N-S, Liu S

Oncology | Follicular Lymphoma

Duration 2hrs San Diego, USA

Patient Preferences for Fixed Versus Treat-to-Progression Therapies in Chronic Lymphocytic Leukemia

Ravelo A, Myers K, Ervin C, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C

Oncology | Chronic Lymphocytic Leukemia

Duration 2hrs San Diego, USA

Integrative Analysis of the Tumor Microenvironment to Model the Molecular Heterogeneity Correlating with Response to Cevostamab in Relapsed/Refractory Multiple Myeloma (RRMM)

Hamidi H, Nakamura R, Roy S, Rajasekaran K, Diaz G, Dos Santos C, Sumiyoshi T

Oncology | Multiple Myeloma

Duration 2hrs San Diego, USA

Glofitamab Plus R-CHOP Induces High Response Rates With a Manageable Safety Profile in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Topp MS, Tani M, Dickinson M, Ghosh N, Santoro A, Pinto A, Bosch F, Fox CP, Lopez Guillermo A, Gastinne T, Viardot A, Townsend W, Qayum N, Barrett M, Kaufman D, Wu C, McCord R, Baumlin P, Kimes P, Morschhauser F

Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Unmet Medical Needs Amongst Older Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting

Kadia T, Bataller A, Ma E, Patel A, Wang R, Yellow-Duke A, Montez M, Bui CN, Ravandi F

Oncology | Acute Myeloid Leukemia

06:45 AM

Duration 15mins Grand Hall B

Fixed-Duration Mosun-Pola has Promising Efficacy and a Manageable Safety Profile in Patients with Prior-BTKi Treated Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Wang ML, Assouline S, Kamdar M, Ghosh N, Naik S, Nakhoda SK, Chavez J, Jia T, Pham S, Huw L-Y, Jing J, Ead W, To I, Batlevi CL, Wei MC, Budde LE

Oncology | Mantle Cell Lymphoma

11:15 PM

Duration 15mins Seaport Ballroom ABCD

Mosunetuzumab and Polatuzumab Vedotin Demonstrate Preliminary Efficacy in Elderly Unfit and Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Olszewski AJ, Eradat H, Avigdor A, Horowitz NA, Babu S, Levi I, McKinney M, Lee ST, Burgues JMB, Rodriguez A, Bastos-Oreiro M, Ganzel C, Kim TM, Jeon Y-W, Taszner M, Narkhede M, Kim WS, Shin H-J, Lavie D, Woszczyk D, Dunshee D, Kapp AV, Zhou M, Batlevi CL, Ead W, Sellam G, Jurczak W

Oncology | Diffuse large B cell lymphoma

Duration 2hrs San Diego, USA

Glofitamab Results in Cost Savings Versus Epcoritamab in Diffuse Large B-Cell Lymphoma (DLBCL): A Total Cost of Care Analysis

Mahmoudjafari Z, Di Maio D, Li J, Rosettie KL, Masaquel A

Oncology | Diffuse large B cell lymphoma

12:00 AM

Duration 15mins Seaport Ballroom ABCD

Glofitamab Plus R-CHOP has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated Large B-Cell Lymphoma Defined as High Risk by Circulating Tumor DNA: Preliminary Safety and Efficacy Results

Falchi L, Jardin F, Haioun C, Wrobel T, Joergensen J, Bastos-Oreiro M, Mou E, Martinez Lopez J, Budde LE, Bartlett NL, Zaucha JM, Garcia-Sancho AM, Shah R, Rees N, McCord R, Bazeos A, Tandon M, Doral M, Troy-Barnes E, Nijland M

Oncology | B Cell Lymphoma

02:00 AM

Duration 2hrs San Diego, USA

Real-World Incidence, Characteristics and Management of Cytokine Release Syndrome Induced by Chimeric Antigen Receptor T-Cell Therapies Across Hematological Malignancies

Chaudhary N, Roy S, Lin C-F, Tandon M, Kwan A, Kuebler P, Shewade A

Oncology | B Cell Lymphoma - Multiple Myeloma

Duration 2hrs San Diego, USA

Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials

Panse J, Cermak J, Kyselova J, Gotoh A, Sahin F, Schrezenmeier H, Chang A, Gentile B, Uguen M, Han B

Hematology | Paroxysmal Nocturnal Hemoglobinuria

Duration 2hrs San Diego, USA

Biomarker Analyses in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Rculizumab: Results from the Phase III Randomized COMMODORE 2 Trial

Lundberg P, de la Iglesia S, Kelly R, Kulasekararaj A, Nishimura J, Risitano A, Röth A, Buatois S, Chebon S, Patel H, Kiialainen A

Hematology | Paroxysmal Nocturnal Hemoglobinuria

Duration 2hrs San Diego, USA

Evaluation of Immune Reconstitution in Patients with Relapsed/Refractory Multiple Myeloma Treated with Cevostamab in Phase I Study GO39775

Miglo J, Choeurng V, Nakamura R, Cooper J

Oncology | Multiple Myeloma

Duration 2hrs San Diego, USA

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Hutchings M, Avigdor A, Sureda A, Terol MJ, Bosch F, Corradini P, Stauffer Larsen T, Rueda Dominguez A, Skarbnik A, Jørgensen J, Lavie D, Gurion R, Zinzani PL, Pinto A, Cordoba R, Bottos A, Li D, Relf J, Filézac de L’Etang A, Sellam G, Gritti G

Oncology | B Cell Lymphoma

Duration 2hrs San Diego, USA

Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience

Jiménez-Yuste V, Lim E, Mistry K, Ventriglia G, Shapiro A

Hematology | Hemophilia A

Duration 2hrs San Diego, USA

Quality of Life in Emicizumab-treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - An Assessment of Baseline PROMIS®-29 Scores

Buckner TW, Daoud N, Lee L, Lim E, Schwartz J, Raimundo K, Recht M

Hematology | Hemophilia A

Duration 2hrs San Diego, USA

Early Intervention with Celmods, but Not Imids, Prevents Relapse to Forimtamig Driven By GPRC5D-Negative Myeloma Cells

Eckmann J, Lechner S, Bayer C, Hage C, Klein C, Umaña P

Oncology | Multiple Myeloma

I am a healthcare professional

Notice

Cookies

External site

ASH 2023